| Literature DB >> 27169484 |
Ramin A Morshed1, Megan E Muroski2, Qing Dai3, Michelle L Wegscheid1, Brenda Auffinger1, Dou Yu2, Yu Han2, Lingjiao Zhang1, Meijing Wu2, Yu Cheng4, Maciej S Lesniak2.
Abstract
As therapies continue to increase the lifespan of patients with breast cancer, the incidence of brain metastases has steadily increased, affecting a significant number of patients with metastatic disease. However, a major barrier toward treating these lesions is the inability of therapeutics to penetrate into the central nervous system and accumulate within intracranial tumor sites. In this study, we designed a cell-penetrating gold nanoparticle platform to increase drug delivery to brain metastatic breast cancer cells. TAT peptide-modified gold nanoparticles carrying doxorubicin led to improved cytotoxicity toward two brain metastatic breast cancer cell lines with a decrease in the IC50 of at least 80% compared to free drug. Intravenous administration of these particles led to extensive accumulation of particles throughout diffuse intracranial metastatic microsatellites with cleaved caspase-3 activity corresponding to tumor foci. Furthermore, intratumoral administration of these particles improved survival in an intracranial MDA-MB-231-Br xenograft mouse model. Our results demonstrate the promising application of gold nanoparticles for improving drug delivery in the context of brain metastatic breast cancer.Entities:
Keywords: brain metastatic breast cancer; chemotherapeutics; drug delivery; metastatic microsatellites; nanoparticles
Mesh:
Substances:
Year: 2016 PMID: 27169484 DOI: 10.1021/acs.molpharmaceut.6b00004
Source DB: PubMed Journal: Mol Pharm ISSN: 1543-8384 Impact factor: 4.939